Federal Bank share price dropped 6% after reporting a 5% YoY decline in net profit for Q3 FY25, despite strong operating profit and improved asset quality. The bank’s accelerated provisions and higher provisions impacted profits. Analysts JPMorgan and UBS maintained “Buy” ratings, with revised target prices, noting slower growth but strong operational performance.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected
January 30, 2025